To investigate the efficacy and safety of Tegafur, gimeracil and oteracil potassium (S-1) combined with Oxaliplatin in elderly patients over 75-year-old with advanced colorectal cancer.

A retrospective study was performed on 70 cases of patients over 75-year-old with advanced colorectal cancer who were admitted from January 2010 to June 2018.According to the different treatment regimens, the patients were divided into the combination group of S-1 and Capecitabine, with 35 cases in each group.There were 31 males and 4 females in the S-1 combined group.Aged (80.4± 3.2) years old, ranging from 75 to 86 years old.Capecitabine combined group included 29 males and 6 females.Aged (80.3±2.9) years old, ranging from 75 to 85 years old.The S-1 combined group was treated with the regimen of S-1 combined with Oxaliplatin.On day 1, Oxaliplatin 85 mg/m²+ 5% glucose injection 250 ml was intravenously injected for 2 hours.At the same time, the dose of S-1 was selected according to the body surface area, and taken orally for 1 to 14 days.Capecitabine combined group was treated with Capecitabine combined with Oxaliplatin, and on day 1, Oxaliplatin 85 mg/m²+ 5% glucose injection 250 ml was intravenously drip for 2 hours.At the same time, Capecitabine was taken orally for 1 to 14 days.The efficacy and adverse reactions occurrence situation of chemotherapy were compared between the two groups.

In S-1 combined group and Capecitabine combined group, the response rates (RR) were 45.7% (16/35) and 42.9% (15/35), respectively, and the disease control rates (DCR) were 77.1% (27/35) and 71.4% (25/35), respectively.There were no significant differences between the two groups in RR and DCR (P>0.05). The occurrence of thrombocytopenia [37.1%(13/35)]was higher in S-1 combined group than in Capecitabine combined group [14.3%(5/35)]and there was significant difference between the two groups (P<0.05). Whereas there were no significant differences between the two groups in the incidences of leukocytopenia, anemia, gastrointestinal reaction, liver function damage, hand-foot syndrome and peripheral neurotoxicity (P>0.05).

For elderly patients over 75-year-old with advanced colorectal cancer, S-1 combined with Oxaliplatin chemotherapy can achieve similar effects as the Capecitabine combined with Oxaliplatin chemotherapy and their side effects are acceptable, and elderly patients can tolerate them well.

Tegafur, gimeracil and oteracil potassium; Oxaliplatin; Capecitabine; Colorectal cancer; Chemotherapy